Australia Pet Veterinary Diets - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The australia pet veterinary diets market size is projected to expand from USD 360 million in 2025 and USD 390.30 million in 2026 to USD 584.70 million by 2031, registering a CAGR of 8.40% between 2026 and 2031. This report is Segmented by Sub Product (Diabetes, Renal, Urinary Tract Disease, Digestive Sensitivity, Oral Care Diets, Derma Diets, and More), by Pets (Cats, Dogs, and Other Pets), by Distribution Channel (Convenience Stores, Online Channel, Specialty Stores, Supermarkets/Hypermarkets, and Others). The Market Forecasts are Provided in Terms of Value in USD and Volume in Metric Tons.

Australia Pet Veterinary Diets Market Trends and Insights

Rising Pet Humanization and Willingness to Pay for Prescription Nutrition

Australian pet owners increasingly consider pets as integral members of their households, driving higher spending on therapeutic pet diets. According to Animal Medicines Australia, Australian pet ownership remained at a record 73% of households in 2025, equivalent to 7.7 million pet-owning homes caring for 31.6 million companion animals. The organization also reported that Australians spent AUD 21.3 billion (USD 13.5 billion) on pet-related products and services during the year, of which AUD 9.8 billion (USD 6.2 billion) was allocated to pet food, highlighting the category's dominant share of overall pet expenditure. As this younger demographic becomes a larger segment of the customer base, the Australian pet veterinary diets market benefits from a growing pool of owners who are more inclined to adopt premium medical nutrition. This trend also supports longer treatment adherence, as owners who view food as part of therapy are less likely to revert to standard diets after initial symptom improvement.

Higher Veterinary Diagnosis Rates for Chronic Conditions

The Australia pet veterinary diets market is positively influenced by the earlier diagnosis and prolonged management of chronic conditions. According to PetSure Pty Ltd’s 2025 Pet Health Monitor, which analyzed claims from over 700,000 insured pets, gastrointestinal conditions, urinary tract disorders, and skin infections and allergies are among the most common reasons for treatment in cats and are also significant conditions in dogs. These conditions are notable as they often necessitate long-term dietary adjustments rather than short-term treatment cycles. Chronic conditions such as kidney disease, urinary disease, food sensitivities, and inflammatory bowel disease require ongoing dietary management, driving repeat purchases on 30-90 day intervals. This makes therapeutic nutrition a more stable category compared to acute care, where demand fluctuates with single episodes. Additionally, Greencross introduced IDEXX Cancer Dx blood-based lymphoma screening into its Senior Lifestage wellness plans in 2025, highlighting the growing adoption of earlier diagnostic pathways in routine care. As diagnostic standards improve, the Australia pet veterinary diets market is positioned to capture more first-time prescriptions and sustain recurring demand through follow-up care.

High Price Premium Versus Maintenance Pet Food

Price remains a significant constraint on the widespread adoption of therapeutic diets across the broader pet-owning population. The Australia pet veterinary diets market experiences strong clinical demand. However, sustained usage largely depends on pet owners' ability to manage recurring costs that exceed those of standard pet food. According to Animal Medicines Australia, in 2025, 12% of pet owners required financial assistance for veterinary care, while 18% of cat owners and 14% of dog owners reported making health-related compromises, such as delaying check-ups or reducing medications. Similarly, PetSure Pty Ltd’s 2024 Pet Health Monitor revealed that half of the surveyed pet owners reduced their spending on veterinary care, with 21% delaying visits to observe the situation before seeking treatment. This trend is critical because prescription diets are most effective when combined with continuous follow-up care, rather than being used solely during acute health episodes. When food, consultation, medication, and insurance premiums are paid in a single month, some households revert to maintenance diets despite veterinary recommendations. As a result, affordability remains a key limitation on volume growth in the Australia pet veterinary diets market, particularly outside high-income metropolitan areas.

Other drivers and restraints analyzed in the detailed report include:

• Clinic-Linked Compliance Improves Reorder Frequency
• E-Commerce Prescription Fulfillment Expands Access Beyond Major Cities
• Prescription and Labeling Compliance Limits Digital Conversion

Segment Analysis

Digestive Sensitivity accounted for 17.7% of the Australia pet veterinary diets market size in 2025, while Oral Care Diets are projected to achieve the fastest growth, with a 9% CAGR through 2031. Digestive products remain the largest category, as gastrointestinal issues are among the most common claims for insured pets in Australia. This provides veterinarians with a consistent rationale for recommending dietary interventions. Oral care diets are experiencing faster growth as dental disease is increasingly recognized as a broader health issue rather than merely a cosmetic concern. This shift has encouraged pet owners to adopt preventive diets for extended periods. Renal and urinary tract disease diets remain stable in volume, as these conditions often require lifelong nutritional management after diagnosis. According to PetSure Pty Ltd, urinary tract disorders were among the most expensive conditions for cats aged 1-8 years in 2024, with average treatment claims of AUD 1,519 (USD 964) per episode, driving demand for diets aimed at reducing recurrence.

The market is increasingly moving toward multi-condition formulations, which reduce the need for separate diets within a single household. For example, Hill’s launched Prescription Diet Metabolic + j/d in April 2026, followed by k/d + Derm Complete and k/d + z/d Hydrolyzed in June 2026. These products address two conditions within one feeding plan, enhancing convenience and improving compliance, particularly for older pets with overlapping health issues. Additionally, Royal Canin renewed its obesity research partnership in March 2026, and Dechra Pharmaceuticals PLC introduced SPECIFIC Heart and Kidney Support Hydrolysed diets in April 2026, highlighting the continued focus on obesity and renal care as key product areas. While diabetes and other veterinary diets remain smaller segments, they are gaining importance as feline obesity and related metabolic conditions receive increased clinical attention from veterinarians.

Complete Report Scope:

• By Sub Product
  • Diabetes
  • Renal
  • Urinary Tract Disease
  • Digestive Sensitivity
  • Oral Care Diets
  • Derma Diets
  • Obesity Diets
  • Other Veterinary Diets
• By Pets
  • Cats
  • Dogs
  • Other Pets
• By Distribution Channel
  • Convenience Stores
  • Online Channel
  • Specialty Stores
  • Supermarkets/ Hypermarkets
  • Other Channels

List of Companies Covered in this Report:

• Mars, Incorporated
• Nestlé S.A. (Purina)
• Colgate-Palmolive Company (Hill's Pet Nutrition, Inc.)
• EBOS Group Limited
• The Real Pet Food Company
• Virbac
• Vetalogica Pty Ltd
• Hypro Pet Foods Pty Ltd
• Ziwi Limited
• Greencross Pet Wellness Company
• Farmina Pet Foods
• Dechra Pharmaceuticals PLC
• General Mills, Inc. (Blue Buffalo)
• Lyka

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support